Amyris seals $255 million development and commercialization deal for cannabinoids

February 6, 2019 |

In California, Amyris announced that it has signed a binding term sheet for a planned cannabinoid development, licensing and commercialization partnership valued at up to $255 million (not including significant royalties once the products are commercialized) with a confidential partner. The $255 million in payments include an upfront payment and the remainder are linked to milestones that are expected over the next 12-36 months following the signing of a definitive final agreement. Amyris has a successful track record of leveraging its unique technology platform to scale No Compromise™ sustainable products and successfully bring them to commercialization. In addition to lab-based milestone payments, this agreement also provides for significant milestone payments for commercially scaling each product.

Print Friendly, PDF & Email

Tags: , ,

Category: Producer News

Thank you for visting the Digest.